Analyses / HCA
Large-cap hospital operator. Valuation looks moderate on earnings, but the stock fell 4.96% on the day and provider data leaves several gaps.
A free account reveals HCA's entry zone, price target & stop loss. Full 1-week to 1-year price forecasts are included with Pro.
The Thesis
▲ Bull Case
Earnings multiples look moderate: P/E 14.9x (price vs. annual profit), forward P/E 14.9x, EV/EBITDA 11.1x (enterprise value vs. cash earnings). EPS grew 13.9% and revenue 7.9%, with a 15.8% operating margin. Price is about 60% of the way up its 52-week range. If the day's drop proves sentiment-driven rather than fundamental, the multiple and margin profile could support a rebound toward the 1-month target band.
▼ Bear Case
Shares fell 4.96% in one session, and the payload gives no cause. Insider activity is net reducing: 64 sell transactions vs. 44 buys, with about 221.7M shares disposed vs. 184.6M acquired. Tangible book value is negative (-$44.78/share), and the current ratio is 0.97. Regulatory headlines, including a CMS proposed anti-fraud rule, add policy uncertainty for hospital operators.
Valuation
FAIRLY VALUED — score 60/100
Earnings and EBITDA multiples are moderate. Price-to-book is not usable because of a data conflict. Growth is positive but not high.
Technical Levels
Support · $472.90 (Day low) · $440.00 (Stop reference (analyst framework level)) · $353.99 (52-week low)
Resistance · $498.78 (Day high) · $501.19 (Prior close) · $556.52 (52-week high)
RSI: Not available in payload
Financial Health
Score 45/100. Short-term liquidity is thin and tangible equity is negative. Leverage and coverage ratios are missing, so the balance sheet cannot be fully assessed from this payload.
Catalysts
| CMS proposed anti-fraud rule across Medicare, Medicaid/CHIP, and Marketplace (provider headline cites possible $90B savings over 10 years) | Ongoing comment and rulemaking period | Medium to high: could affect hospital reimbursement and compliance costs |
| Next quarterly earnings report (date not in payload) | Not in payload | High: would test EPS growth (13.9%) and revenue growth (7.9%) against the current multiple |
Risk Flags
See HCA's full trade plan — free
Create a free account to unlock the exact entry, target, and stop — plus run live analysis on any of 5,000+ tickers. No card required.
Unlock HCA free →Recent News
- Best Stocks to Buy for the New CongressYahoo
- Reported November 16, U.S. CMS Issues Proposed Rule To Target Fraud Across Medicare, Medicaid/CHIP, And The Marketplace; Sees Possible Savings Of $90B Over Next 10 YearsBenzinga
- Why Is Everyone Ignoring DaVita Stock's High Cash Yield?Yahoo
- Commure Acquires Elaborate to Cure the Clinician InboxYahoo
- A $22 Billion Fund Bought These 3 StocksYahoo
You've read your 2 free analyses
Create a free account for unlimited analyses — every name on the page, plus live tools on 5,000+ tickers. No card required.
Read the full HCA analysis — free →Free to read · 2 analyses every 30 days without an account
More Analyses
HCA FAQ
Is HCA a buy right now?
HCA Healthcare, Inc.'s current read is a Pullback watch: mixed read after a sharp down day setup with medium confidence over a 1-3 months horizon. Valuation: FAIRLY VALUED. See the full bull and bear case above, or run a live analysis for the exact entry, target and stop.
Is HCA overvalued?
FAIRLY VALUED (valuation score 60/100). Earnings and EBITDA multiples are moderate. Price-to-book is not usable because of a data conflict. Growth is positive but not high.
What are the risks of buying HCA?
Shares fell 4.96% in one session, and the payload gives no cause. Insider activity is net reducing: 64 sell transactions vs. 44 buys, with about 221.7M shares disposed vs. 184.6M acquired. Tangible book value is negative (-$44.78/share), and the current ratio is 0.97. Regulatory headlines, including a CMS proposed anti-fraud rule, add policy uncertainty for hospital operators.